avesthagen final
Post on 11-Nov-2014
68 Views
Preview:
DESCRIPTION
TRANSCRIPT
India’s leading integrated systemsbiology platform company
focus
convergence between food, pharma and population genetics
develop products forpredictive, preventive and personalized healthcare
EthosAVESTHAGEN LIMITED
HealthcareNutrition
Business Model | Product Strategy
Systems Biology
Predictive Preventive
Personalized
bioNutrition bioAgriculturebioPharmaceuticals
Technologies | Products
AVESTHAGEN LIMITED
Business Model | Alliances Strategy
bio
Nu
trit
ion
bio
Ag
ricu
ltu
re
bio
Ph
arm
ace
uti
cals
Alliances
AVESTHAGEN LIMITED
Avesthagen Platform
Early Research
Trials & Validation Production
bioNutrition
Early Research
Crop Development Trials Regulatory
bioAgriculture
Product Development
Partner(s)
Marketing
Marketing
Subsidiary(ies)Avesthagen
Lab Scale
Process Development
API Production
Regulatory Approvals
bioPharmaceuticalsMarketing
Business Model | Growth through PartnershipAVESTHAGEN LIMITED
Biomarker Discovery
pDx + PVx + PRx*
2008 2010+ 2015+
- pDx + Fx - pDx + Rx
Nutrigenomics pDx + PFx + PRx
Clinically Validated Bioactives (Fx)
* Includes biopharmaceuticals and bioactives products
pDx + PVx + Rx
Predictive / Preventive (p)
bioNutrition
Personalized (P)
AVESTAGENOMEPredictive Diagnostics (pDx)
bioPharmaceuticals
Business Model | Product Development StrategyAVESTHAGEN LIMITED
Group Structure | Global FootprintAVESTHAGEN LIMITED
Group Structure | ShareholdingAVESTHAGEN LIMITED
Dr. Villoo Morawala-PatellChairperson
Founder and Managing Director, AVESTHAGEN LIMITED
Mr. Darius E. UdwadiaVice Chairman
Founding partner of Udwadia & Udeshi, Solicitors & Advocates
Mr. Emmanuel Rougier
Directors
Deputy CEO, Groupe Limagrain
Mr. Jochen Ebert Managing Director, Danone India Pvt. Ltd.
Prof. Marc Van Montagu Founding Director of IPBO
Mr. Nadir Godrej Managing Director of Godrej Industries
Mr. K Ravindra Chief Risk Officer, ICICI Venture Fund
Mr. Koen Wentink Chief of Logistics, AVESTHAGEN LIMITED
Board of DirectorsAVESTHAGEN LIMITED
Dr. Helle Bechgaard Vice-Chairman, Dankse Bank, Denmark
Mrs. Farah Morawala-Patell-SochaInstitute of Biotechnology, Cambridge University
Ms. Sanaya Morawala-Patell Institute of Biochemistry, Cambridge University
Prof. Frank Gannon Director General, Science Foundation Ireland, Previously Director of EMBO
Dr. Robert L. Strausberg Deputy Director, J Craig Venter Institute
Prof. Satyajit Mayor Cellular Organisation & SignallingNational Centre for Biological Sciences
Prof. N.K. Ganguly Distinguished Biotechnology Fellow & AdvisorTranslational Health Science & Technology InstituteDepartment of Biotechnology, National Institute of Immunology
Scientific Advisory BoardAVESTHAGEN LIMITED
Prof Rita Colwell Distinguished Professor, University of Maryland,John Hopkins Institute of Public Health, Previously Director of the National Science Foundation, USA
Prof. G. Padmanabhan Honorary Professor, Department of BiochemistryIndian Institute of Science, Previously Director of IISc.
Dr. Sven Thormahlen Director General Danone Research
Dr. Chris Bowler Molecular Marine Biology, Ecole Normale Supérieure, Paris
Dr. Jean-Pierre Isal Independent Consultant (Previously Senior VP, Quintiles)
Dr. Villoo Morawala-Patell Founder and CMD
Mr. Samaresh Parida Chief Operating Officer
Mr. Bruce Murdoch Chief Business Officer
Mr. Supriyo Guha Company Secretary
Dr Rajesh Ullanat Chief Scientific Officer, bioPharmaceuticals
Dr Sami Guzder Chief Scientific Officer, Science & Innovation
Mr. Koen Wentink Chief Logistics Officer
Management Team
Dr Renuka Jain Chief Scientific Officer, BioNutrition
Mr. Pierre Socha Vice-President, Corporate Development
Dr. Anil Ram Chauhan Vice-President, Operations and Corporate Affairs
AVESTHAGEN LIMITED
Financial Investors
Strategic Investors
ICICI Ventures India
Fidelity International
Danone France
Limagrain France
Godrej Industries IndiabioMérieux France
Tata Industries India
Key Shareholders
Cipla India
New York Life USA
AVESTHAGEN LIMITED
180Inventions
bioPharma
MetabolicEngineering
bioAgriculture
bioNutrition
Diagnostics
IP PortfolioAVESTHAGEN LIMITED
IP PortfolioAVESTHAGEN LIMITED
Type of Application Indian USA EU Australia S. Africa Korea TotalPatents Granted 2 2 1 2 1 1 9
Group Inventions Application/FilingsbioAgriculture 46 74bioNutrition 75 145bioPharmaceuticals 13 98Science and Innovation 46 29TOTAL 180 346
Patents
Avesthagen has been granted 9 patents across different countries, the details of which is provided below. Additionally, a total of 346 patent applications are pending today in different jurisdictions.
IP PortfolioAVESTHAGEN LIMITED
Business AGT General bioNutrition bioAgriculture S&I Total
Copyrights Granted 1 3 1 2 7Copyright Applications 4 4 - - 8
Copyrights
7 copyrights have been granted, of which 5 are in India and 2 in the United States.
Another 8 copyright applications are pending.
The distribution of the copyrights across the business is given below.
IP PortfolioAVESTHAGEN LIMITED
Business AGT General bioNutrition bioAgriculture S&I bio Pharma Total
Trademarks Registered 5 40 1 - - 46Trademark Applications 17 23 6 2 1 49TOTAL 22 63 7 2 1 95
Trademarks
46 trademarks have been Registered and a further 49 trademark applications are pending in India. The distribution of these across the business is given below.
bioNutritionbioNutrition
Strategy & Product PipelineStrategy & Product Pipeline
Mission StatementbioNutrition
Global nutrition platform specializing in the discovery, development and marketing of branded and clinically validated plant based bioactives aimed at degenerative conditions.
In the near future, Avesthagen will bring new products for B2C and B2B markets developed in collaboration with private / public partners
With the convergence of Avestagenome and Drug Discovery efforts new personalised bioactives will be launched
Availability of extensive databases that include a widerange of products used in traditional systems of medicine practiced in India and SEA and a compendium of herbal medicines used across the world.
A proprietary methodology called MetaGridTM, which is based on the use of sophisticated high-throughput instrumental analysis.
Validation of the activity of compositions using tissue specific gene expression profiling (micro-arrays) and highly targeted cell and animal models of human diseases.
Strategy | Proprietary ToolsbioNutrition
ADePt TM
MetaGrid TM
Effective Clinical R&D model
MetaGridTM
Strategy | R&DbioNutrition
Strategy | Product PipelinebioNutrition
Diabetes
Clinical trials completed
Lowers Glycemic Index
Snacks
Pre-clinical trials completed
Insulin mimetic and sensitization activity
Beverage and snacks
Pre-clinical trials completed
Insulin mimetic and sensitization activity
Beverage and snacks
Govad Pre-clinical trials completed
Lowers Glycemic Index and Insulin sensitization
Snacks and beverages
Pre-clinical trials completed
Insulin mimetic and sensitization activity
Snacks and beverages
Mohor Pre-clinical trials completed
Insulin sensitization Snacks and beverages
Teestar
ASPAND
Brand Name Status Functionality Food Application
Gosh
Health Condition
Strategy | Branded BioactivesbioNutrition
Bone Health
Pre-clinical trials completed
Promotes bone formation
Snacks and beverages
Pre-clinical trials completed
Promotes bone formation
Snacks
Pre-clinical trials completed
Reduces bone resorption
Snacks and beverages
Cardiovascular Health
Pre-clinical trials completed
Lowers cholesterol Beverages and Snacks
Antioxidant Clinical trials completed Cell rejuvination
Snacks and beverages
Brand Name Status Functionality Food Application
Health Condition
Strategy | Branded BioactivesbioNutrition
2008 2010+ 2015+
Nutrigenomics pDx + PFx + PRx
Bioactives Abbreviated Trials
FFM
Foods
Nutraceuticals
Strategy | Product PositioningbioNutrition
Nutrigenomics pDx + PFx + PRx
Health Foods Abbreviated Trials
Rx Clinically Validated
Nutrigenomics pDx + PFx + PRx
OTC drugs Abbreviated Trials
Bioactives Clinically Validated
Functional Foods Clinically Validated
Discovery, development and marketing of branded therapeutic nutritional bioactives aimed at degenerative conditions, especially diabetes and weight management, CVD, osteoarthritis and osteoporosis, stress and cancer.
Joint product optimization and development
Joint testing and validation with marketing partner
Exclusive Manufacturing rights to Avesthagen
Marketing of product
Avesthagen entitled to royalties and milestone payments / success fees
Joint IP ownership
Business Model
Partner(s)Subsidiary(ies)
Avesthagen
Early Research
Trials & Validation Production
Product Development Marketing
bioNutrition
For specified product categories
bioNutrition
Strategy | B2B - Collaborations
Strategy | B2C - Functional FoodsbioNutrition
Functional Foods using active ingredients developed by Avesthagen (launch May 2008)
Muesli & Breakfast Cereals (7 variants)
Whole Wheat Crackers (6 variants)
Bars (4 variants)
Ethnic Snacks (end 2008)
Strategy | B2C - Functional FoodsbioNutrition
Salient features
Reduces blood glucose levels
Maintains optimum body weight
100% Natural
Zero trans fat
Ideal ratios of SFA: MUFA: PUFA
Good source of dietary fibers
Prebiotic
Suitable for pre diabetics
Suitable for calorie conscious
No added artificial colours, flavors or preservatives
Approx. Nutrition facts (per 100g)
Energy
(kcals)
Carbs
(g)
Protein
(g)
Fat
(g)
Fiber
(g)
384.02 53 11.46 10 18.09
Recommended serving: 4-5 crackers twice a day
Whole Wheat Crackers – with TEESTAR™
Strategy | B2C - Functional FoodsbioNutrition
Value Proposition
A healthy and natural treat, Good Earth Whole Wheat Crackers, are light, heart-friendly and easy to digest.
High Fibre content from wheat bran used in its original form.
Zero Trans fat which means lower blood cholesterol levels and reduced risk of cardiovascular problems.
An ideal healthy snack to be eaten at anytime of the day
Plain Wheat, Ground Garlic, Roasted Sesame, Crushed pepper, Flaked Chilli & Toasted Jeera
Strategy | B2C - Functional FoodsbioNutrition
Whole Wheat Crackers
Strategy | B2C - Functional FoodsbioNutrition
Breakfast Cereals
Good Earth Muesli Bars Value Proposition
On-the-go snack, keeps you going until your next meal.
Natural fruits and almonds provide micronutrients essential for maintaining good health.
High proteins from skimmed milk and soy protein repair damaged cells owing to intense physical activity
Presence of sugars and assimilated carbohydrates result in instant and sustained energy.
Available in three variants -, Apple Cinnamon , Cocoa Dates Almonds and Orange Peel Raisins Dates
Strategy | B2C - Functional FoodsbioNutrition
Launched in US Market
Launch in India : mid 2008 EU Launch : end 2008
Strategy | B2C - OTCbioNutrition
Strategy | B2C - OTCbioNutrition
Fundamental changes in the dynamics of the healthcare industry are the driving growth of the nutrition industry :
An increasingly aging population
The increasing cost of healthcare
The growing trend towards self-medication
The growing consumer interest in alternatives to pharmaceuticals
Nutrition is being increasingly recognized as a major avenue for healthcare
Consumer is increasingly aware of the linkage between health and nutrition
The Dietary Supplement and Health and Education Act (DSHEA)
Market | Industry DynamicsbioNutrition
Cardio-vascularDiesease
Cancer Diabetes Over-weight& Obesity
OtherChronic
All Other TotalHealthcare
cost
$ Billions
Source: CDC, US Dept of Health & Human Services
33%
20%
11%
10%9%
17%100%
Cost Distribution by Disease State (2005)
74% of Total Costs
CVD Cancer Diabetes Obesity Other Chronic
All Other Total Healthcare
Cost
$653 $396 $226 $209 $190 $342 $2,016$ Billions
Market | “Big Four” Health ConditionsbioNutrition
Functional foods
The global market is estimated to be USD 85 billion in size in 2006, growing at a rate of 8-9% p.a. USA, Europe and Japan are the largest markets for functional foods.
Dietary supplements
The global market for dietary supplements is estimated at USD 68 billion (2006), and is exhibiting a growth rate of 4-5% per annum. The US is the largest market for dietary supplements, with an estimated market size of USD 22 bn.
Global functional ingredient sales
Global ingredient sales are estimated at USD 9.4 billion for 2006. This constitutes USD 7.6 bn. as supply to the supplement market, and USD 1.8 billion as supply to the functional food market.
Source: Nutrition Business Journal November 2007
MarketsbioNutrition
bioPharmaceuticals bioPharmaceuticals
Strategy & Product PipelineStrategy & Product Pipeline
Mission Statement
Strategy for biosimilars though partnering for cost effective healthcare focusing on mammalian blockbusters with high entry barrier.
In the near future, Avesthagen will bring new biopharma technologies and products developed in collaboration with private / public partners
With the convergence of Avestagenome and Drug Discovery efforts new personalised biopharmaceuticals will be launched
bioPharmaceuticals
Co-funded Development program for pipeline of Biosimilars with high entry barriers
Avesthagen responsible for development and manufacturing
Partner responsible for marketing of product
Avesthagen entitled to 20% royalties on net sales of the products
IP shared between partners equally
Manufacturing facilities for biologicals (being setup in India + Acquisition in Germany + dialogues on with other Asian countries)
Business Model
Partner(s)Subsidiary(ies)
Avesthagen
Lab Scale
Process Development
API Production
Regulatory Approvals Marketing
bioPharmaceuticals
Product PipelinebioPharmaceuticals
RevenuesbioPharmaceuticals
RevenuesbioPharmaceuticals
cGMP facility, Bangalore, India
Phase 1 –Phase 1 – Setup of pilot scale manufacturing facility To be completed by third quarter 2008 Capacity 200 L bioreactor (2 low/medium dosage molecules) cGMP qualified facilities – 2 x 200 L & 1000 L (Germany and Malaysia)
Phase 2 –Phase 2 – Setup of large scale manufacturing facility Capacity – 10,000 lt bioreactor with DSP infrastructure Will be completed by late 2010 cGMP qualified Will be certified by the USFDA Acquisition of manufacturing plant
an option being investigated
cGMP facilityBerlin, Germany
Manufacturing | SitesbioPharmaceuticals
Bangalore PDLCell line DevelopmentProcess Development
2 Projects at a time
Bangalore GMPPre-clinical materialClinical material50L / 150LOne project
Berlin PDLCell line DevelopmentProcess Development
1 Project at a time (currently)
Kleinmachnow GMPPre-clinical materialClinical material50L / 200L(Two) projects at a time
Innobiologics PDLProcess Development
30LOne project
Innobiologics GMPPre-clinical materialClinical material30L / 300L / 1‘000LOne project
CMO1‘000 L
Indian Operations German Operations
Malaysian Operations3rd Party Operations
Manufacturing | Networking of project sitesbioPharmaceuticals
The Total world market for Biological products in 2007 was valued at Euros
60 billion and market value of the Biosimilar product portfolio is Euros 15
billion.
The Therapeutic segments that Avesthagen ‘s Biosimilar pipeline are
directed, which includes, Autoimmune disease, Cancer and Blood disorders
are valued at Euros 70 billion worldwide and INR 4 billion in India.
Market | Entry Strategy bioPharmaceuticals
AVESTHAGENBIOSIMILARS
2011 - 2018
EU/US/REGULATED
EUR 15 bil
BRIC MARKETS
EUR 2 bil
INDIAN MARKETS
EUR 600 mil
2010 - 2012
2009 - 2012
bioPharmaceuticals
Market | Entry Strategy
Market | Entry Strategy bioPharmaceuticals
The first products will be launched in India in 2009 and 2010 followed by
BRIC countries and then EU and USA once Patents begin to expire on the
products.
The Market entry strategy for India and BRIC countries is to market
through the largest Pharmaceutical company in India- Cipla Ltd (market
share of 6%.) Cipla will participate in Clinical Phases, Regulatory approval,
Formulation and Marketing. Revenue will come from API sales and
Royalties.
The Market entry strategy for EU, USA and Regulated markets is to
secure strong market partners early in the Clinical Development and
Regulatory process to market beginning 2011/12. Revenue will come from
Licensing, Milestones, API sales and Royalties.
Collaborations bioPharmaceuticals
Ongoing discussions
• Medium sized Pharma company based in Vienna, EU
• Large Biopharma company (No.2) based in EU
• Large Biopharma CMO and supplier based in Basel, EU
New discussions
• Large Pharma company moving into Biologics, US
Collaborations bioPharmaceuticals
bioAgriculturebioAgriculture
Strategy & Product PipelineStrategy & Product Pipeline
Mission Statement
Avesthagen Seed Promise: To build credibility with farmers and commitment to excellence while growing as a profitable enterprise.
To improve productivity in Agriculture and develop technologies that address global environmental challenges to achieve a sustainable future through a fine blend of food, feed, fibre and fuel.
bioAgriculture
Strategy | Market entry
bioAgriculture
Petroleum ApplicationsFuel, Oil Lubricants
Fibre ApplicationsEquipments, Clothing Construction
Industrial ApplicationsPlastics, Food Stuffs, Adhesives
2008 2010+ 2015+
Other Applications
Animal HusbandryNutrition / AdditivesFeeding / Sheltering
Environment Adjusted CropsNutrition-FITTM : DHA, ALA, LycopeneStress Resistance : Drought-FITTM, Salinity-FITTM
Hybrid-FITTM
Food & Feed
Development of Environment Adjusted plants for food, feed, fuel and fibre
Avesthagen takes ideas to proof-of-concept stage and partners for development of products
Joint green house testing and field validation with a) marketing partner or b) Atash Seeds Pvt Ltd (subsidiary)
Avesthagen entitled to licensing fees, milestone payments / success fees and royalties
Joint marketing of product
Joint IP ownership
Partner(s)Subsidiary(ies)
Avesthagen
Business Model | Environment Adjusted CropsbioAgriculture
Early Research
Crop Development Trials Regulatory
Marketing
Market | Global Area of Biotech CropsbioAgriculture
Source : International
Seed Federation, 2008
Market | Domestic MarketsbioAgriculture
Field Crop Varieties Wheat, Rice and Peas
Field Crop Hybrids Rice, Cotton, maize, Sunflower, sorghum, pearl millet, and tur dal
Vegetable Hybrids Tomatto, Chilli, Brinjal, Cabbage, Cauliflower,
Beans, Gourds, Greens and Melons
bioAgriculture
Product Pipeline | 1st generation (Atash Seeds)
Public - Private Collaborations
Hybrid Pigeonpea (ICRISAT)Millet (ICRISAT)Drought Rice (UAS)
bioAgriculture
Product Pipeline | 2nd generation
Hybrid-FITHybrid-FITTMTM
Salinity-FITSalinity-FITTMTM
Drought-FIT Drought-FIT TMTM Nutrition-FITNutrition-FITTMTM
Rice
Tomato
Tomato
Rice
Pearl Millet
Rice
Sunflower
Mustard
Marker Assisted Marker Assisted Selection / Breeding Selection / Breeding
Bio-fuelsBio-fuels
Maize
Rice
Jatropha
Product Pipeline | 3rd generation
Barley
bioAgriculture
Nutrition-FITTM
High Anti oxidant Rice (Non GM)
Collection of over ninety lines Currently in field for multiplication Analysis for antioxidant content, 2008 Large scale cultivation, 2008 High antioxidant Rice based product, 2009 Market Launch Globally, 2009 Estimated rice production 2008, 423 Million Tons Coloured Rice Market Globally: Over 100 M USD
Product Pipeline | 3rd generationbioAgriculture
Nutrition-FITTM
Product Pipeline | 3rd generationbioAgriculture
High Lycopene Tomato
– Analysis for antioxidant content, 2007– A range of 250-500% increase in Lycopene– Currently analysing fruits of third generation– Selection of plant and tissue culture, 2008– Permission for Protected Cultivation trial, 2008– Large scale Greenhouse cultivation, 2009– High Lycopene tomato puree product development, 2009– GM Lycopene product development, 2009– Market Launch 2011– Market Size 2009 for lycopene sales will surpass $26 million,
according to Frost & Sullivan
Drought-FITTM
Product Pipeline | 3rd generationbioAgriculture
Drought tolerant Indica Rice (MAB) ~ 2009 Single gene Japonica rice (GM) ~2011 Multigene gene Indica rice (GM) ~ 2012
Drought-FITTM
Product Pipeline | 3rd generationbioAgriculture
Drought tolerant Indica Rice (MAB) Checked in All India Trials Best Material so identified for drought tolerance Currently in mass production Variety Product launch in 2009 Hybrid Product Launch in 2011 Rice Variety seed market, Rice Hybrid seed market,
Drought-FITTM
Product Pipeline | 3rd generationbioAgriculture
Single gene Japonica rice (GM) Four Generations Checked in Greenhouse Strip trials permission to RCGM, 2008 Large Scale Field Trail, 2009 Commercial Seed Production 2010 Launch of GM drought tolerant Transgenic Japonica rice, 2011 Estimated market for drought tolerant variety, 50 M USD
Drought-FITTM
Product Pipeline | 3rd generationbioAgriculture
Multi gene Indica Hybrid rice (GM) Generating T0’s, parent for hybrid 2008 Greenhouse trials, 2009 Hybrid Seed Production, 2010 Strip trials permission to RCGM, 2011 Large Scale Field Trail, 2012 Commercial Seed Production 2013 Launch of GM drought tolerant Transgenic Hybrid Indica rice, 2013 Estimated market for drought tolerant hybrids, over ~100 M USD
Male Sterile slender long grain rice ~ 2011 Male Sterile Tomato ~ 2011 Male Sterile Wheat ~ 2013
Hybrid-FITTM
Product Pipeline | 3rd generationbioAgriculture
Drought-FIT TM
Nutrition-FITTM
Hybrid-FITTM
High Anti oxidant Rice (Non GM): 2009 High Lycopene products: 2011
Drought tolerant Indica Rice (MAB) ~ 2009 Single gene Japonica rice (GM) ~ 2011 Multigene gene Indica rice (GM) ~ 2012
Male Sterile slender long grain rice ~ 2011 Male Sterile Tomato ~ 2011 Male Sterile Wheat ~2013
Product Pipeline | 3rd generation – SummarybioAgriculture
Atash SeedsbioAgriculture
CollaborationsbioAgriculture
Normal plasticNormal plastic
05/05
BioperceptTMBioperceptTM
BioperceptTM
bioAgriculture
The twenty first century will be defined as a “plastic age”.
Mankind uses more plastics than iron & steel.
Single use plastic bags are the single largest source of solid waste pollution in the world today. These bags float around and stay in our air, water and land for a thousand years. Often termed as “white pollution”, countries around the world have taken steps to control this problem.
In India and in the Middle East, Avesthagen's presence and its strategic relationship with Limagrain has enables us to taken steps to introduce BioperceptTM – fully biodegradable and compostable plastic bags.
Biopercept TM addressing a need
BioperceptTM
bioAgriculture
Science & Innovation Science & Innovation
Predictive, Preventive & Personalised Healthcare
Mission StatementScience & Innovation
Science & Innovation focus on Preventive, Predictive and Personalised Healthcare through Systems Biology
Science & Innovation is core to Avesthagen's business of science strategy, an integrated platform of biotechnology and bioinformatics delivering Innovation with Systems Biology.
Science & Innovation enables new product development and Partnership building.
Predictive, Preventive Predictive, Preventive & Personalised Healthcare & Personalised Healthcare
- Systems Biology
- Avestagenome Project TM
- Natural Product Drug Discovery
Biochemistry Systems Biology
One Size fits all drugs Personalized medicine
Aging Stem Cells Therapy
Therapeutics / Diagnostics Theranostics
Treating Sickness Preventing Sickness
Avesthagen leads global change
Food for survival Food for health
Fossil fuels Alternative Energy
Predictive, Preventive & Personalised Healthcare
Systems BiologyPredictive, Preventive & Personalised Healthcare
Confluence of Technology, Tools and Knowledge
penicillinssulphonamidesaspirin
psychotropics
NSAIDS
H2-antagonistsbeta blockers
lipid lowerersACE-inhibitors
Biotech drugs
chronicdegenerativedisease associatedwith ageing,inflammation,cancer
drugs againsttargets identifiedfrom disease genes
1900 20301950 1960 1970 1980 1990 2000 2010 2020 2040
New
The
rape
utic
Cyc
les
1st generation 2nd generation 3rd generation
natural productsand derivatives
serendipity
receptors
enzyme
genetic engineering
cell pharmacology/molecular biology
genomics/ proteomics
So
urc
e:
CM
S,
Le
hm
an
Bro
the
rs r
ese
arc
h
New Tools for Drug DiscoveryPredictive, Preventive & Personalised Healthcare
Diabetes Type 2: What’s Becoming Possible?
Avesthagen | Product Development StrategyFood – Pharma Convergence
Source : Burrill & Company
Biomarker Discovery
pDx + PVx + PRx*
2008 2010+ 2015+
- pDx + Fx - pDx + Rx
Nutrigenomics pDx + PFx + PRx
Clinically Validated Bioactives (Fx)
* Includes biopharmaceuticals and bioactives products
pDx + PVx + Rx
Predictive / Preventive (p)
bioNutrition
Personalized (P)
AVESTAGENOMEPredictive Diagnostics (pDx)
bioPharmaceuticals
Avesthagen | Product Development StrategyFood – Pharma Convergence
Predictive, Preventive Predictive, Preventive & Personalised Healthcare & Personalised Healthcare
- Systems Biology
- The AvestagenomeTM Project
- Natural Product Drug Discovery
Overview
Predictive, Preventive and Personalized Healthcare:
A systems biology study of the Parsis to determine the genetic basis of longevity and age-related disorders.
The AvestagenomeTM Project
Ideal Population
The Parsis are well defined small population of less than 70,000 individuals in India
Concentrated in and around Mumbai Well documented genealogical charts demonstrating an
unbroken lineages for 30 generations Generations of marriage within the community has resulted in
increased positive traits - greater longevity diseases - Parkinson’s disease, stroke, heart disease, specific cancers, and Alzheimer’s disease.
Ideal population to study the interplay of multiple genes, environment and health factors
OverviewThe AvestagenomeTM Project
Market value of biomarker discovery
There are as many as 17 groups of diseases and wellness aspects in our project
Disease Market value
Cancer $35bn (Datamonitor report 2005-01-06)Arthritis $10bn (IMS health reports 2007)Diabetes $15bn (Leaddiscovery report 2006-03-27)
Other diseasesHeart diseases Thyroid DiseasesKidney Diseases Blood PressureLung Diseases Systemic Lupus ErythematosisMultiple Sclerosis Mental IllnessProstate Disease Gynecological ProblemsGenetic Disorders Neurological Disorders (Parkinson’s)Glucose-6-Phosphate Dehydrogenase Deficiency Asthma
Markets The AvestagenomeTM Project
Arthritis: Market and Opportunity
Disease Facts:
Poor prognosis leads to: - Aggressive treatment - Development of disease modifying antirehumatic drugs (DMARD)
Market needs:
- Arthritis Market value is $10bn
- There is a need to develop new strategies for Biomarker identification & nutritional products to prevent and/or treat Arthritis
IMS health reports 2007, Frost & Sullivan 2004 and Nature Reviews Drug Discovery 4, 11-12 (January 2005)
The AvestagenomeTM Project
Markets | Age related conditions
Projected Alzheimer’s Disease Prevalence
The AvestagenomeTM Project
Markets | Age related conditions
Distribution of cancer cases in Parsis and the general population of Mumbai, 2002-04.(Data obtained from the Bombay Cancer Registry, Mumbai)
The AvestagenomeTM Project
Conditions | Cancers prevalence
Phase 1Systems Biology approach for Biomarker Discovery(eg. Osteoarthritis)
Archival
Biomarkers
HTS Genetic sequenceAnalysis (Genome, SNP etc.)
Gene ExpressionMicroarray
Metabolomics
Proteomics
Bioinformatics
Disease information
Strategy | R&DThe AvestagenomeTM Project
DNA and RNA Plasma & Serum Clinical & scientific Data
Blood collection
Phase 2Biomarkers to Drug Discovery
Biomarkers for Longevity - Preventive and Predictive Healthcare- Wellness and nutritional products
Disease Biomarkers - Personalized Healthcare
Validation of Biomarkers
Assay Development
Bioactive/Drug Screening
Nutritional/wellness products &
Drugs for Healthcare
Strategy | R&DThe AvestagenomeTM Project
Dis
ea
se
Bu
rde
n
Time
Co
st
1/r
ev
ers
ibil
ity
Typical Current
Intervention
Earliest Clinical
Detection
Earliest Molecular Detection
Initiating Events
Baseline Risk
Decision Support Tools:
Baseline Risk Preclinical Progression
Disease Initiation and Progression
Assess Risk Refine Assessment Predict/Diagnose Monitor Progression
Predict Events
Inform Therapeutics
Sources of New Biomarkers:
Stable Genomics:
SNPs Haplotype Mapping Gene Sequencing
Dynamic Genomics: Gene ExpressionProteomics Metabolomics
Therapeutic Decision Support
Strategy | R&DThe AvestagenomeTM Project
The Molecular Basis of Biological Processes
Alterations in Disease
New Targets for Dx, Rx, Vx
The Molecular Heterogeneity of Disease
Disease Subtypes
Right Rx forDisease
Individual Genetic Variation
Pharmaco-genetics
New Targets for Dx, Rx, Vx
DiseasePredisposition
PDxPRx
Analyzing the Molecular Profiles (Biosignatures) of Body Functions in Health and Disease
Strategy | R&DThe AvestagenomeTM Project
Study design
Database construction
Blood collection
Genotyping
Association Mapping
Sequenom Analysis
Transcriptome profiling
Metabolome
Plasma proteins
Stem Cells
Molecular Diagnostics
2007-08 2008-09 2009-10 2010-11 2011-12 2012-13
Avestagenome work flow for biomarker identification
Strategy | R&DThe AvestagenomeTM Project
Outcomes | HealthcareThe AvestagenomeTM Project
Source : Burrill & Company
Outcomes | HealthcareThe AvestagenomeTM Project
Source : Burrill & Company
Outcomes | HealthcareThe AvestagenomeTM Project
Source : Burrill & Company
Outcomes | HealthcareThe AvestagenomeTM Project
Source : Burrill & Company
Outcomes | HealthcareThe AvestagenomeTM Project
Source : Burrill & Company
Outcomes | HealthcareThe AvestagenomeTM Project
Source : Burrill & Company
The AvestagenomeTM Project
Outcomes | Safer, More Effective Drugs
The same way that drugs work well for some people and not others, some people…
- Eat high fat diets and not show evidence of atherosclerosis. WHY?
- Have high cholesterol and not die of heart attacks. WHY?
Nutrigenomics
Outcomes | NutritionThe AvestagenomeTM Project
Outcomes | NutrigenomicsThe AvestagenomeTM Project
Source : Nature Publishing
Outcomes | NutrigenomicsThe AvestagenomeTM Project
Outcomes | NutrigenomicsThe AvestagenomeTM Project
Outcomes | NutrigenomicsThe AvestagenomeTM Project
Outcomes | NutrigenomicsThe AvestagenomeTM Project
Outcomes | Nutrition
The Avestagenome ProjectTo understand an individual’s response to nutrition through the analysis of their unique genetic make up
bioNutritionTo match an individual to his food and allows development of safe and effective dietary treatments
The AvestagenomeTM Project
Blood Collection
Biomarkers Discovery
Biomarkers ValidationBiobank
Rx, Fx, Vx, Dx Development
Partner(s)
Avesthagen
Strategy | Business ModelThe AvestagenomeTM Project
Tie-up with Global players in Diagnostics, Vaccines, Pharma and Nutrition as well as Public bodies
Joint product optimization and development
Joint testing and validation with marketing partner
Partner responsible for marketing of product
Full IP ownership with Avesthagen
Commercial used of the outcomes to be based on Territories, Health Conditions and Uses/Products.
Avesthagen entitled to royalties and milestone payments / success fees
Production & Marketing
Diagnostics
Nutrigenomics Technology Partners
Strategy | CollaborationsThe AvestagenomeTM Project
Clinicals
Predictive, Preventive Predictive, Preventive & Personalised Healthcare & Personalised Healthcare
- Systems Biology
- Avestagenome Project TM
- Natural Product Drug Discovery
Strategy | Screening of FFM bioactivesNatural Product Drug Discovery
Initial Bioactive Sample
Bioactive Concentrate
Pure Bioactive Compound
Novel Bioactive Compound
PotentialLead
Known Compounds
Structure Determination
Processing Experiments
Bio-assays guided Fractionation
Evaluation of “natural SAR”Shotgun synthesis of derivativesScale-up purification
Medicinal Chemistry
Development Track
Candidate
bioNutrition Science & Innovation
Strategy | Antarctica ProjectNatural Product Drug Discovery
What’s happening in Stem Cells?
Natural Product Drug Discovery
Strategy | Stem Cells
Human nerve stem cells transplanted into rats' damaged spinal cords have survived
Found: Stem Cells Responsible for Pancreatic Cancer
Mother's Stem Cells Passed to Baby—Suggests Possible Way to Treat Diabetes
Stem Cell Lines Generated from Amniotic Fluid
Multipotent Adult Progenitor Cells (MAPCs) Regenerate Blood in Mice
Treatments for Alzheimer’s and Multiple Sclerosis
Regeneration and repair of periphery nerves
Repair damaged heart muscle and improve cardiac function
Stem-cell transplantation for refractory or relapsing lymphomas
Research Programmes
Avesthagenome
Cancer
Cardiovascular
Hepatoxicity
Macular/Optic Nerve Regeneration
Red Blood Cells
Adult Stem Cells
Natural Product Drug Discovery
Strategy | Stem Cells
“This mouse offers proof that researchers can create embryonic stem cells without using an egg. It grew from an embryo containing cells that had been reprogrammed to an embryonic state.”
Source: Whitehead Institute for Biomedical Research
Strategy | CapabilitiesNatural Product Drug Discovery
CHEMISTRY & ASSAYSMedicinal ChemistryAnalytical ChemistrySynthetic Chemistry
Computational ChemistryChemioinformatic
BioChemical AssaysCell Based Assays
Stem Cells (Screening)
CLINICAL & REGULATORYPreclinicals & Clinicals
Regulatory & Ethical approvals
BIOMARKERS & TARGETSStudy Design & Sample collection
Genotyping - SequencingTranscriptome (Gene Expression)
Metabolite IdentificationProteome ProfilingStatistical Analysis
Bioinformatics
Natural Product Drug Discovery
Strategy | Business Model
CollaborationsDrug Discovery
FinancialsFinancials
Profit & LossAVESTHAGEN LIMITED
Profit & LossAVESTHAGEN LIMITED
Funds RequirementAVESTHAGEN LIMITED
Avesthagen is a 650 employee company well-regarded worldwide for its uniqueness and leading position in India
Closure of Series-C early 2007 & IPO scheduled for 2008-2009
Product driven group and launch of new ones in 2007 across our businesses.
Strong and innovative IP portfolio with more than 151 inventions, 341 Patent applications and 100 applications on Copyrights & Trademarks
Profitable for three consecutive years (excl. exceptional items) with strong top line growth
Solid back-up from strategic and financial investors
Long-term commitments from partners / clients
Multiple top international certifications and awards
Significant infrastructure expansion
Strong management team
MilestonesAVESTHAGEN LIMITED
THANK YOU
top related